openPR Logo
Press release

Approval for commercialization of Heberprot-P® in Mexico

05-04-2018 05:09 PM CET | Health & Medicine

Press release from: Center for Genetic Engineering and Biotechnology

Approval for commercialization of Heberprot-P® in Mexico

Havana, Cuba, May 4, 2018 – Heberprot-P® has been approved for commercialization in México. The Center for Genetic Engineering and Biotechnology (CIGB) is excited to announce regulatory approval of this innovative medicine indicated for advanced diabetic foot ulcer (DFU), which is expected to save thousands of people from lower limb amputation. The official approval date of Heberprot-P® was April 30th, 2018. Heberprot-P® stimulates granulation, accelerates DFU re-epithelization, and reduces healing time, surgical debridement, amputation risk, and recurrences. The intralesional infiltration of Heberprot-P® may be applied in combination with Good Wound Care (GWC), revascularization, and antibiotics. This medicine is an effective solution for an unmet medical need, a first in class product, unique worldwide, for DFU treatment. It is the only therapeutic choice available for advanced and complex DFU, reluctant to healing (grades 3, 4, and 5, according to Wagner’s classification).

Clinical experience derived from the intervention with Heberprot-P® in daily medical practice in Cuba was analyzed in 2013 in a study that reviewed the evolution of more than 2 000 patients as well as the pharmacovigilance of 1 788 patients, showing a 75% probability of granulation response, 61% healing rate, 71% amputation risk reduction, Bayes' favorable factor (5.40), and complete granulation in 76% of ulcers in 5 weeks (Adv. Pharmacoepidem. 2013, 2 (2): 1000128; BMC Pharm. & Toxicol, 2013, 14: 44). The International Working Group of Diabetic Foot (IWGDF) evaluated results of the clinical trial performed with Heberprot-P® in Cuba and reported in 2009 as promising, highlighting the results obtained in only 2 weeks of treatment (Diabetes Metab Res Rev 2012; 28 (Suppl 1): 119-141).

In a later systematic review, clinical trials comparing the use of growth factors with GWC (Cochrane Database of Systematic Reviews 2015, Issue 10, Art. No. CD008548), the IWGDF’s evaluation was reported on all major issues and requirements of Heberprot-P® clinical trials in Cuba. Similar criteria were expressed by the IWGDF in the guidelines on DFU healing (IWGDF Guidance, 2015: 10). A fourth study reported similar observations on the intralesional EGF infiltration method: "... a highly significant difference between groups in the prevalence of granulation tissue after just 2 weeks" (Diabetes Metab Res Rev 2016; 32 (Suppl 1): 154- 168).

Results of clinical studies performed in Cuba, Russia, Turkey, Vietnam, Argentina, Mexico, and Ukraine were enough to demonstrate safety and efficacy profile of Heberprot-P®. This medicine has been used in more than 290 000 patients with diabetic foot ulcer (DFU) in Russia, Belarus, Georgia, Ukraine, Turkey, Algeria, China, Panama, Argentina, Cuba, Dominican Republic, Venezuela, Ecuador, Libya, Uruguay, Paraguay, Colombia, Guatemala, Philippines, Vietnam, Nicaragua, Saudi Arabia, Indonesia, Seychelles, Saint Lucia, Saint Vicente, Sri Lanka, Jordan, and Kuwait.

A national survey of health and nutrition in Mexico reported that prevalence of diabetes is 9.4% of total population, which sums up more than 11 million people, 9.1% of adult diabetic suffers DFU, and amputation is indicated to 5.5% of adult diabetics (National Survey of Health and Nutrition, INEGI 2016). According to recent reports, lower limb amputation is the unique alternative for 45% of diabetics with advanced DFU in Mexico (Diabet. Foot. Ankle. 2017 Sep 6, 8 (1): 1367210). In a previous study, similar results were reported: 42% patients with advanced DFU required major amputation (Wound Repair & Regen. 24 (5): 923-927).
Written by Jose A. Buxado, MSc., Assistant Researcher, CIGB.

The Center for Genetic Engineering and Biotechnology of Havana is an institution devoted to research, development, manufacturing, and commercialization of products and technology derived from life science.

Alyane Vazquez González, BA., Communication & Media, e-mail: alyane.vazquez@cigb.edu.cu. Ave 31 e/ 158 y 190, Playa, P.O. Box 6162, Habana 10600, Cuba.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Approval for commercialization of Heberprot-P® in Mexico here

News-ID: 1040333 • Views:

More Releases from Center for Genetic Engineering and Biotechnology

Researchers defeat cancer once again
Researchers defeat cancer once again
Havana, September 17, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce positive outcomes of an innovative medicine developed by CIGB's researchers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba, and registered with
CIGB’s researchers defeat cancer once again
CIGB’s researchers defeat cancer once again
Havana – September 13, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce favorable results of an innovative medicine developed by Cuban researchers and engineers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba,
President of India visits CIGB today to reinforce bilateral trade and scientific cooperation
President of India visits CIGB today to reinforce bilateral trade and scientific …
Havana, June 22nd, 2018 - The 14th and current President of India, in office since July 25th 2017, Ram Nath Kovind (b. 1945) visited the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba. President Ram Nath Kovind was received by the President of BioCubaFarma, Dr. Eduardo Martínez, and the General Director of the CIGB Dr. Eulogio Pimentel. This is a very important date in the agenda of Mr.

All 4 Releases


More Releases for DFU

Diabetic Foot Ulcer (DFU) Therapeutic Market Outlook and Future Projections for …
The diabetic foot ulcer (dfu) therapeutic market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only
Advanced Wound Care DFU: Diabetic Foot Ulcers
How Does Diabetes Affect Wound Care? Diabetic foot ulcers are a serious problem related to diabetes. Diabetic foot ulcers (DFUs) are known to affect 15 percent of patients with diabetes. They are also known to be complex and challenging. This is due to chronic inflammation, biofilm, and extracellular matrix degradation. For those that develop a DFU, approximately 6% will be hospitalized due to infection or other related infections. These
Diabetic Foot Ulcer (DFU) Therapy Market 2022 Outlook, Current and Future Indust …
Diabetic Foot Ulcer (DFU) Therapy Market report offers one of the best solutions to know the trends and opportunities in industry. Diabetic foot ulcer is a major complication of diabetes mellitus, and probably the major component of the diabetic foot. Diabetic foot ulcers are among one of the major global medical issues. Management of diabetic foot ulcers aims at fast healing and wound closure, by adopting a multidisciplinary therapeutic approach
Diabetic Foot Ulcer (DFU) Treatment Market 2021 | Detailed Report
According to Market Study Report, Diabetic Foot Ulcer (DFU) Treatment Market provides a comprehensive analysis of the Diabetic Foot Ulcer (DFU) Treatment Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in this report is collected by research and industry experts team. Get Free Sample PDF (including full TOC, Tables and Figures) of Diabetic Foot Ulcer (DFU) Treatment Market
New Opportunities in Diabetic Foot Ulcer (DFU) Market 2021 Growth, Segmentation
The Global Diabetic Foot Ulcer (DFU) Market report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of the Global Market. Global Diabetic Foot Ulcer (DFU) Market research report offers extensive research and analysis of key aspects of the global Global Diabetic Foot Ulcer (DFU) market. The report on Global Diabetic Foot Ulcer (DFU) Market covers big geographical, as well as sub-regions throughout
Global Diabetic Foot Ulcer (DFU) Treatment Market To Record Exponential Growth D …
"The Zion Market Research added a new report “Diabetic Foot Ulcer (DFU) Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026” in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting. The global Diabetic Foot Ulcer (DFU) Treatment Market report offers a complete overview of the Diabetic